PriceTargets.com logo

Talis Biomedical - TLIS Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $5.00
  • Forecasted Upside: -45.65%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.20 As of 04/24/2024 01:00 AM ET
▲ +0.19 (2.11%)

This chart shows the closing price for TLIS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Talis Biomedical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLIS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLIS

Analyst Price Target is $5.00
▼ -45.65% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Talis Biomedical in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a -45.65% upside from the last price of $9.20.

This chart shows the closing price for TLIS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 polled investment analysts is to sell stock in Talis Biomedical. This Sell consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2023BTIG ResearchBoost TargetSell ➝ Sell$5.00Low
3/18/2022BTIG ResearchDowngradeNeutral ➝ SellHigh
3/16/2022Bank of AmericaLower TargetUnderperform$45.00 ➝ $22.50High
1/7/2022Bank of AmericaDowngradeNeutral ➝ Underperform$45.00Medium
9/27/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$150.00 ➝ $105.00High
8/31/2021BTIG ResearchDowngradeBuy ➝ NeutralHigh
8/12/2021Piper SandlerDowngradeOverweight ➝ Neutral$195.00 ➝ $135.00Medium
8/11/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$255.00 ➝ $150.00High
5/12/2021Piper SandlerLower TargetOverweight$255.00 ➝ $195.00High
3/9/2021JPMorgan Chase & Co.Initiated CoverageOverweight$270.00High
3/9/2021BTIG ResearchInitiated CoverageBuy$270.00Low
3/9/2021Piper SandlerInitiated CoverageOverweight$255.00Low
3/9/2021Bank of AmericaInitiated CoverageNeutral$210.00Low
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Talis Biomedical logo
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.
Read More

Today's Range

Now: $9.20
Low: $8.77
High: $9.20

50 Day Range

MA: $8.57
Low: $7.94
High: $9.25

52 Week Range

Now: $9.20
Low: $4.35
High: $9.32

Volume

3,351 shs

Average Volume

8,644 shs

Market Capitalization

$16.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Talis Biomedical?

The following Wall Street analysts have issued reports on Talis Biomedical in the last year: BTIG Research.
View the latest analyst ratings for TLIS.

What is the current price target for Talis Biomedical?

1 Wall Street analysts have set twelve-month price targets for Talis Biomedical in the last year. Their average twelve-month price target is $5.00, suggesting a possible downside of 45.7%. BTIG Research has the highest price target set, predicting TLIS will reach $5.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $5.00 for Talis Biomedical in the next year.
View the latest price targets for TLIS.

What is the current consensus analyst rating for Talis Biomedical?

Talis Biomedical currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe TLIS will underperform the market and that investors should sell shares of Talis Biomedical.
View the latest ratings for TLIS.

What other companies compete with Talis Biomedical?

Other companies that are similar to Talis Biomedical include Accelerate Diagnostics, Telesis Bio, Cue Health, Precipio and Singular Genomics Systems. Learn More about companies similar to Talis Biomedical.

How do I contact Talis Biomedical's investor relations team?

Talis Biomedical's physical mailing address is 230 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The company's listed phone number is 650-433-3000 and its investor relations email address is [email protected]. The official website for Talis Biomedical is talis.bio. Learn More about contacing Talis Biomedical investor relations.